Pharmafile Logo

Report: Reinventing product and portfolio value for the biopharmaceutical industry

Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of stakeholders earlier than you think.

- PMLiVE

The last decade has seen a notable rise in complex medicines, which target smaller and more specific patient populations and have novel modes of action. Often, determining the value of these treatments requires knowledge and communications about novel biomarkers, newer forms of evidence, and complex clinical pathways.

An interconnected network of stakeholders— regulators, payers, healthcare professionals, patients, and carers—therefore need to comprehend vast amounts of information to determine a product’s value above the standard of care. Each of these stakeholders have overlapping and distinct information needs, and it is unlikely their requirements can be fully addressed by clinical trials alone.

The regulatory environment is supportive of accelerated approvals based on Phase 2 single-arm studies and surrogate endpoints, leading to significant uncertainty for payers looking to understand the incremental treatment benefit of a product versus a reimbursed standard of care. This tension has created challenges for manufacturers who must fully understand different stakeholders’ needs and develop integrated plans to deliver against these requirements.

Biopharmaceutical companies need to rethink their approach to clinical and economic value. Taking a structured approach will help uncover stakeholders’ questions and knowledge gaps at the earliest phases of clinical development.

By collaborating cross-functionally, manufacturers can build a holistic picture of each stakeholder upfront and create early alignment around the evidence gaps and benefits that will resonate with their target stakeholders. These insights will determine the evidence-generation plan, in turn improving clinical study design, generating focused patient insights, and providing the foundation for the real-world evidence strategy. Most importantly, patients’ lives and their health outcomes can be improved.

In this report, our Medical, Consulting, Policy, Access, Value, and Evidence experts detail the practicalities of taking this multistakeholder approach, which emphasizes the benefits that resonate with each stakeholder group.

Download a copy of the magazine here

This content was provided by Avalere Health

Company Details

 Latest Content from  Avalere Health 

Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs

Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.

Fishawack Health becomes Avalere Health, uncovering the potential in every product and the possibilities for every patient

As a single united organization, the company seamlessly connects science and creativity, technology and data, and ability and agility to ensure patients receive life-changing innovations faster.

Industry leader Amar Urhekar joins Fishawack Health as Chief Operating Officer to integrate interdisciplinary teams across capabilities

As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.

Fishawack Health appoints Chief People Officer to spearhead integration of talent and culture across geographies

Fishawack Health welcomes Harriet Shurville to the team as Chief People Officer to spearhead integration efforts, champion diversity and inclusion, and cultivate an environment where interdisciplinary teams thrive.

Archetypes: Rethinking go-to-market expectations to drive commercial success

In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...

Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer

Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

The challenges of reimbursement and innovative pricing for cell and gene therapies

Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...

Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech...

Fishawack Health welcomes Mario Muredda as its new President of Marketing

Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.